Corporate Income Tax - Addition Modification - Direct-to-Consumer Pharmaceutical Advertising

File HB484 ("Corporate Income Tax - Addition Modification - Direct-to-Consumer Pharmaceutical Advertising") is before the Maryland Legislature and has not been decided. Latest step (January 23, 2026): Hearing 2/12 at 1:00 p.m.

Maryland file HB484, before the Maryland Legislature. No action in 301 days as of 2026-01-23.

Official summary

Official synopsis: Providing an addition modification under the corporate income tax for the amount of certain direct-to-consumer advertising expenses for certain covered drugs paid or incurred during the taxable year that are deducted under the Internal Revenue Code; and applying the Act to all taxable years beginning after December 31, 2025.

Read the official record for HB484

See everything up for a vote · This week in Maryland · See what we have filed with the clerk